Adolescents and adults with eosinophilic esophagitis improved with dupilumab regardless of whether they were practicing food ...

high rheumatoid factor (RF) titers, and the presence of anti-SSA were associated with an increased risk for RA-CPFE. Additionally, levels of IgG and IgM autoantibodies to HBEC were elevated in RA-CPFE ...

Regeneron Pharmaceuticals (NASDAQ ... The main reason is the extremely high competition in the PD-1/PD-L1 checkpoint inhibitors market, which includes Merck's Keytruda, Bristol-Myers Squibb's ...

“Meaning I'd hide a pack of cigarettes on a high cupboard shelf and only smoke if I was sure ... The treatment Lyn refers to is the monoclonal antibody dupilumab (brand name Dupixent), which works by ...

Table 1. Overview of studies on hyposensitization of people with allergic contact dermatitis caused by sensitizers other than Rhus and nickel. One patient: remission of MF, no further need to ...

Regeneron Pharmaceuticals announced positive three-year results from an extension study of EYLEA HD (aflibercept) Injection 8 mg for treating wet age-related macular degeneration (wAMD). The ...

More than 1,000,000 patients are currently being treated with Dupixent globally. Dupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement. To date, dupilumab ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...

SAN FRANCISCO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is facing mounting pressure on multiple fronts. Following disappointing sales figures and ongoing ...

Eye­Point Phar­ma­ceu­ti­cals, a biotech at­tempt­ing to grab a sliv­er of Re­gen­eron’s share of the de­gen­er­a­tive eye dis­ease mar­ket, said six-month re­sults show its ...

We are now emerging also as the leaders in high throughput proteomics as reflected by the selection of the Regeneron Genetics Center to generate the proteomics data for the UK Biobank Pharma ...